Welcome to our dedicated page for Eli Lilly and news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly and stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly (NYSE: LLY) launched the Lilly Employer Connect platform on March 5, 2026 to expand employer-sponsored access to obesity medicines. The program starts with over 15 independent program administrators and offers Zepbound KwikPen at a discounted price of $449 per device across all doses to participating network pharmacies.
The platform enables flexible cost-share models and nationwide pharmacy support, while preserving provider and patient choice. Clinical data cited include SURMOUNT-1 (15 mg: 20.9% mean weight loss at 72 weeks vs 3.1% placebo) and SURMOUNT-5 open-label comparisons.
Eli Lilly (NYSE: LLY) announced a positive CHMP opinion recommending Olumiant (baricitinib) for adolescents ages 12 to <18 with severe alopecia areata. The recommendation is based on Phase 3 BRAVE-AA-PEDS results showing 42.4% achieved ≥80% scalp hair coverage at 36 weeks (4 mg).
The opinion moves to the European Commission for final action, expected in one to two months; a U.S. decision is expected in the second half of 2026.
Chondrosarcoma market (covering 7MM) is forecast to grow from 2026–2036 as diagnosis improves and new therapies advance. Approximately 1,400 incident US cases were reported in 2024–25. Emerging drugs include Ozekibart (INBRX-109), TIBSOVO (ivosidenib), and LY3410738 (LLY), with planned regulatory filings and ongoing pivotal trials.
The pipeline remains limited; however, Fast Track designations, positive Phase II topline data, a planned BLA in Q2 2026, and a Phase III primary completion expected Feb 2028 could reshape care for unresectable and metastatic disease.
Eli Lilly (NYSE: LLY) reported 52-week ACHIEVE-3 results showing oral orforglipron outperformed oral semaglutide on A1C and weight. At 36 mg, orforglipron reduced A1C by 2.2% vs 1.4% and produced 9.2% weight loss (19.7 lbs) vs 5.3% (11.0 lbs).
Orforglipron improved multiple cardiovascular risk factors, had higher treatment discontinuation rates, and has regulatory submissions in >40 countries with potential U.S. obesity action in Q2 2026.
Eli Lilly (NYSE: LLY) announced FDA approval of a four-dose, single-patient Zepbound KwikPen that delivers a month of treatment in one device. The KwikPen joins single-dose vials and is available by prescription with LillyDirect self-pay pricing starting at $299/month for 2.5 mg. Clinical highlights cited include SURMOUNT-1 (15 mg: 20.9% mean weight loss at 72 weeks) and SURMOUNT-5 (average 50 lb loss vs 33 lb with comparator).
The release reiterates safety warnings, dosing options (2.5–15 mg) and contraindications for MTC and MEN 2.
Eli Lilly (NYSE: LLY) reported long-term VIVID program results showing durable Crohn's disease control with Omvoh (mirikizumab-mrkz): among patients who achieved outcomes at Year 1, clinical remission 92.4%, corticosteroid-free remission 91.2% at Week 152, and sustained bowel urgency improvements.
Post hoc analyses showed nearly 50% fewer Crohn's-related hospitalizations/surgeries weeks 0–12 and nearly 70% fewer during weeks 12–52 versus placebo; Omvoh is approved in 47 countries.
Eli Lilly (NYSE: LLY) reported positive topline 36-week results from the Phase 3b TOGETHER-PsO trial: concomitant Taltz (ixekizumab) plus Zepbound (tirzepatide) met the primary endpoint and all key secondaries versus Taltz alone.
Key results: 27.1% reached PASI 100 plus ≥10% weight loss vs 5.8% (p<0.001); 40.6% achieved PASI 100 vs 29.0% (p<0.05). Mean BMI >39 kg/m2. Adverse events were generally mild to moderate and consistent with known profiles. Detailed 36-week data will be published and discussed with regulators.
Scribe Therapeutics announced a second success milestone in its in vivo CRISPR collaboration with Eli Lilly (NYSE: LLY), advancing a target for neurological and neuromuscular diseases. The achievement further validates Scribe’s X-Editor (XE) platform and CRISPR by Design engineering approach.
Under the 2023 agreement, Scribe is eligible for more than $1.5 billion in potential milestone payments across programs plus low-double-digit royalties, and the companies previously reported an initial milestone and a 2025 ASGCT presentation.
Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will appear in a fireside chat at 3:10 p.m. ET.
A live audio webcast will be available via Lilly's investor site under Webcasts & Presentations, with a replay accessible on the same site for approximately 90 days.
USOPC and Lilly (NYSE:LLY) announced the multi-year Team USA Athlete Recovery Program partnership, covering support after Milano Cortina 2026 through LA28.
The program expands a 2024 pilot that supported 10 athletes (6 qualified for Paris 2024), and Lilly will fund access, storytelling, and program growth over the next three years.